Get started
Author

Karen Cornelissen

Observed names: K CORNELISSEN, K. Cornelissen
ORCID: 0009-0004-4338-4988
Observed ORCID: 0009-0004-4338-4988
OpenAlex ID: A5010908754
Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study
2025 · Johan A Maertens, George R Thompson, et al. · The Lancet Infectious Diseases · 93
Phase I Safety, Tolerability, and Pharmacokinetic Study of Recombinant Human Mannan-Binding Lectin
2006 · Kenneth Ahrend Petersen, Finn Matthiesen, et al. · Journal of Clinical Immunology · 92
Absorption, metabolism and excretion of tamsulosin hydrochloride in man
1996 · Y. Soeishi, H. Matsushima, et al. · Xenobiotica · 38
Relative Contributions of Presystemic and Systemic Peptidases to Oral Exposure of a Novel Metabotropic Glutamate 2/3 Receptor Agonist (LY404039) After Oral Administration of Prodrug Pomaglumetad Methionil (LY2140023)
2014 · William F. Annes, Amanda Long, et al. · Journal of Pharmaceutical Sciences · 21
594. An Open-Label Study in Healthy Volunteers to Determine the Absolute Bioavailability of, the Effect of Food and Dosing by Nasogastric Tube upon the Pharmacokinetics of a Single Oral Dose of Olorofim (OLO)
2022 · Karen Cornelissen, Paul A Newell, et al. · Open Forum Infectious Diseases · 9
Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study
2026 · Johan Maertens, Sharon C A Chen, et al. · Journal of Antimicrobial Chemotherapy · 7
Abstract 11889: Phase Ib Study of Icosabutate, a Novel Structurally Enhanced Fatty Acid, in Subjects With Hypercholesterolemia
2014 · Yan Qin, Jonas Hallén, et al. · Circulation · 6
The tissue distribution and pharmacokinetics of [14C]-olorofim following intravenous dosing in the rat
2026 · Derek Law, John Ayrton, et al. · Journal of Antimicrobial Chemotherapy · 3
595. Olorofim (OLO) for treatment of invasive mould infections in patients with limited or no treatment options: PK data from a Phase 2b open-label study (NCT03583164, Study 32)
2022 · Karen Cornelissen, James G Wright, et al. · Open Forum Infectious Diseases · 3
Absorption, metabolism, and excretion of (H)-ospemifene following a single oral dose to post-menopausal women
2005 · S BRYSON, K CORNELISSEN, et al. · Clinical Pharmacology & Therapeutics · 3
Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim
2026 · Karen Cornelissen, John H. Rex, et al. · Antimicrobial Agents and Chemotherapy · 2
P-1239. Systemic Exposure of Olorofim in Children with Invasive Fungal Infections
2025 · Karen Cornelissen, John H Rex, et al. · Open Forum Infectious Diseases · 2
P-1238. Assessment of Body Weight upon PK of Olorofim in Patients with Invasive Mould Infections
2025 · Karen Cornelissen, John H Rex, et al. · Open Forum Infectious Diseases · 1
PDF
The Pharmacokinetics, Metabolism and Exretion of Sitafloxacin Following A Single Oral Dose to Healthy Male Subjects
2003 · M. Yamaguchi, N. Haque, et al. · Clinical Pharmacology & Therapeutics · 1
Works count: 14
Citation count: 281
H-index: 6
I10-index: 4
Year
Topic
Type